TTX-MC138 + Seviprotimut-L

TTX-MC138 + Seviprotimut-L is a preclinical combination therapy developed by TransCode Therapeutics (formerly Polynoma). This therapeutic approach combines TTX-MC138, an antisense oligonucleotide designed to inhibit microRNA-10b (miR-10b), with Seviprotimut-L, an RNA-based therapeutic vaccine targeting melanoma-associated antigens (specifically STNK/N-K). The mechanism of action involves a dual approach: TTX-MC138 aims to suppress the metastatic process by neutralizing miR-10b, a known driver of cancer cell migration and invasion, while Seviprotimut-L is intended to stimulate a targeted immune response against melanoma cells. This combination is being investigated for immuno-oncology applications, primarily focusing on melanoma and other metastatic cancers where miR-10b is overexpressed.